EC
ARQT icon

EntryPoint Capital’s Arcutis Biotherapeutics ARQT Stock Holding History

EntryPoint Capital’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-17,774
Closed -$165K – 711
2024
Q3 		$165K Buy
17,774
+11,202
+170% +$111K 0.09% 506
2024
Q2 		$61.1K Buy
+6,572
New +$59.4K 0.09% 491

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

EntryPoint Capital's ARQT Position: Q4 2024 in Review

EntryPoint Capital sold out of Arcutis Biotherapeutics (ARQT) in Q4 2024, closing a stake of 17,774 shares — an estimated $165K sold.

EntryPoint Capital first reported a position in ARQT in Q2 2024 and held it in 2 quarters. The position peaked at $165K in Q3 2024. 208 funds tracked by Wall St. Rank hold ARQT as of Q4 2024.

  • EntryPoint Capital reported no remaining Arcutis Biotherapeutics position as of Q4 2024 after selling out during the quarter.
  • EntryPoint Capital sold 17,774 Arcutis Biotherapeutics shares in Q4 2024, an estimated $165K.
  • EntryPoint Capital first reported a position in Arcutis Biotherapeutics in Q2 2024 and held it in 2 quarters.
  • EntryPoint Capital's Arcutis Biotherapeutics position peaked at $165K in Q3 2024.
  • 208 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2024.

Based on EntryPoint Capital's 13F filing for Q4 2024, filed 11 Feb 2025.